INTRODUCTION
High-dose melphalan followed by autologous peripheral blood stem cell transplantation (ASCT) remains the standard treatment for patients with symptomatic multiple myeloma (MM) aged o 65 years. [1] [2] [3] A second ASCT may be needed for patients who do not achieve a very good partial response, 1, 4 for those who relapse or progress after the first ASCT [5] [6] [7] and as a part of a planned tandem transplant program. 8, 9 Therefore, up-front mobilization of a sufficient stem cell yield to perform double ASCT is desired.
There is no consensus on the optimal regimen to recommend for peripheral blood stem cell (PBSC) mobilization in MM. PBSC mobilization can be achieved by the combination of chemotherapy and G-CSF or by G-CSF alone. The combination of chemotherapy and G-CSF was reported to be superior to G-CSF alone in PBSC mobilization [10] [11] [12] [13] but was more toxic. In a phase 3 multicenter randomized study, G-CSF associated with a placebo was reported to mobilize at least 6 × 10 6 CD34+ cells/kg in only 34% of MM patients in 1-2 days and in only 54% after 4 days of aphaeresis. 14, 15 In our institution, collection and storage of a PBSC graft able to ensure two transplants is planned to be done after induction therapy in patients with symptomatic MM aged o65 years. To collect a minimum number of 4 × 10 6 /kg, cyclophosphamide (CY) (4 g/m ) and G-CSF. This retrospective study compares the two regimens for the yield of PBSC collected, toxicity and hematologic recovery after ASCT.
PATIENTS AND METHODS
Clinical records of patients with symptomatic MM eligible for ASCT, who underwent PBSC mobilization from January 2003 to October 2014, were reviewed. Between January 2003 and April 2011, after induction therapy, patients underwent PBSC mobilization with CY: 4 g/m 2 on day 1 followed by a daily administration of G-CSF 5 μg/kg started on day 3 and continued throughout the apheresis period (CY+G-CSF 5 , group 1). Between May 2011 and October 2014 patients underwent PBSC mobilization with VP16: 375 mg/m 2 /days for 2 days followed by a daily administration of G-CSF 10 μg/kg from day 3 and throughout the apheresis period (VP16+G-CSF 10 , group 2). The aim was to collect a minimum number of 4 × 10 6 CD34+cells/kg to permit the realization of a second round of ASCT. Monitoring of blood cell count and CD34+-circulating cells started on day 11 in group 1, and day 8 in group 2. CD34+ cell count was determined according to the International Society of Hematotherapy and Graft Engineering Guidelines 16 with a dual platform technology using a Becton Dickinson FACS Canto II flow cytometer (Becton Dickinson, Oxford, UK) and a cell counter HMX. CD34+ percentages were measured after triple staining for CD45+, CD34+ and 7'AAD to exclude dead cells. After gating of viable cells, CD45+ cells were gated and then analyzed for the percentage of CD34+ cells. CD34+ concentration was calculated by reference to the corrected white cell count of the sample (7'AAD negative and CD45+).
PBSC collection was performed when the peripheral CD34+ cell count was420/μL. Two types of machines were used: the COBE spectra cell separator version 6. 17, 18 Response to treatment was divided in three categories: ' ⩾ very good partial response (VGPR)', 'PR' and 'o PR' according to the International Myeloma Working Group criteria. 19 Analysis of hematopoietic recovery after ASCT excluded patients who received damaged grafts.
RESULTS

Patients' and disease characteristics
Two hundred and ninety-five patients underwent PBSC mobilization. In total, 178 and 117 patients received CY+G-CSF 5 and VP16+G-CSF 10 , respectively. The median age at mobilization was 54 years (range 24-65 years). There were no significant differences in age, sex, stage of the disease, ISS and chromosomal abnormalities between the two groups. The median time between diagnosis and mobilization, the type and the number of lines of prior therapy, and the disease status before the start of the PBSC mobilization were not significantly different between the two groups ( Table 1) .
PBSC collection
Results of PBSC collection are reported in Table 2 .
Two hundred and eighty-seven patients (97.3%) underwent aphaeresis, 171 (96.1%) in group 1 and 116 (99.1%) in group 2 (P = 0.11). Among the eight patients who did not undergo PBSC collection, six (five in group 1 and one in group 2) did not reach 20 CD34+ circulating cells/μl, one in group 1 did not return to hospital for collection and one in group 1 had septic shock, which hampered PBSC collection. Aphaereses started at a median time of 11 days after the mobilization course in the two groups (P = NS). The median volume processed was 2.3 times the estimated patient blood volume with no significant difference between the two groups. Among the 287 patients who underwent aphaeresis, two patients (one in group 1 and one in group 2) did not achieve collection of 2 × 10 6 CD34+ cells/kg. Only one of them underwent a second course of mobilization. The minimum requested dose of 4 × 10 6 CD34+ cells/kg and the target dose of 8 × 10 6 CD34+ cells/kg were achieved more frequently in the VP16+G-CSF 10 group both by the first aphaeresis (P o10 − 4 ) and throughout the collection course (P = 0.064 and P o 10 − 4 , respectively). The rate of good mobilizers was significantly higher in the VP16−G-CSF 10 group (P o 10 − 4 ). For the two groups, the median number of CD34+ cells collected was not significantly different between Cobe Spectra and MCS+ machine.
Among the 10 patients who failed mobilization, seven underwent a second mobilization course (six in group 1 and one in group 2). The remaining three patients refused to undergo a second mobilization course. Three patients (43%) yielded at least 2 × 10 6 CD34+ cells/kg after the second course of mobilization (Table 3) . G-CSF 10 allowed collection of at least 2 × 10 6 CD34+ cells/kg in two out of six patients after CY+G-CSF 5 failure. Plerixafor allowed collection of 3.56 × 10 6 CD34+ cells/kg in one patient. The median number of CD34+cells collected was 3.56 × 10 6 /kg. Two patients (28.5%) underwent ASCT after the second attempt of PBSC mobilization.
Toxicity and supportive care Grade 4 neutropenia and febrile neutropenia were significantly more frequent in patients who received CY+G-CSF 5 . In the latter group, one patient developed septic shock. The median time of hospitalization was significantly reduced and the number of hospitalization days, caused by mobilization, decreased markedly from 133 days per year to 6 days per year with VP16+G-CSF 10 . IV antibiotics were administrated less frequently in the VP16+G-CSF 10 group. Red blood cell transfusions were more frequently required in the CY+ G-CSF 5 group. All the differences were significant (Table 4 ).
ASCT and hematopoietic recovery Among 287 patients who underwent aphaeresis after one mobilization course, 276 underwent ASCT (170 in group 1 and 106 in group 2). ASCT was not performed because of co-morbidities (n = 5), death (n = 4), graft containing o 0.5 × 10 6 CD34+ cells/kg in a patient who refused to undergo a second mobilization course (n = 1) and because of follow-up loss (n = 1). Only 274 patients were evaluated for hematopoietic recovery after ASCT (two patients in group 2 who received damaged grafts were excluded). Details on graft content and hematopoietic recovery are summarized in Table 5 .
DISCUSSION
At our knowledge, this study is the largest study that compared intermediate doses of CY+G-CSF with intermediate doses of VP16+G-CSF in terms of efficacy, toxicity and hematopoietic recovery after ASCT in de novo symptomatic MM patients who, for economic reasons, received during 11 years an induction therapy containing thalidomide and dexamethasone for the majority, although it is no longer considered as the standard of care for newly diagnosed MM patients. We have chosen the cutoff of 4 × 10 6 CD34+ cells/kg as the minimum number of PBSC to collect, in order to perform a second transplant if needed. This option is still relevant in our country for patients who do not reach a very good partial response 1, 4 and for those who relapse or progress after the first ASCT. [5] [6] [7] Because of limited resources, novel and costly drugs such as bortezomib and lenalidomide could be used in these situations for only a few patients and for just three to four cycles as a bridge to a second ASCT, and could not be used for long periods until further progression. For the same reasons, pre-emptive plerixafor currently used for poor mobilizers [20] [21] [22] is available for a very few patients. That is why, chemotherapy+ G-CSF remains the most used regimen in our practice. There are conflicting results on the cost-effectiveness of routine plerixafor compared with ID-CY+G-CSF 10 . It has been reported to be less cost-effective than ID-CY+G-CSF 10 in one study, 23 but more costeffective in a recent retrospective study. 24 At our knowledge, outpatient VP16+G-CSF 10 regimen has not been compared for cost-effectiveness with routine or pre-emptive plerixafor. Our challenge was to use an available, affordable and easily manageable regimen in an outpatients setting, highly effective in mobilizing PBSC and well tolerated for the majority of patients. VP16 introduced since May 2011 and associated to G-CSF 10 was highly effective for PBSC mobilization in our patients. The median CD34+ cell number collected was 12.98 × 10 6 /kg. Ninety-eight percent of our patients collected the minimum requested dose of 4 × 10 6 CD34+ cells/kg to perform two transplants, 89.7% reached the target dose of 8 × 10 6 /kg and 95% were considered 'good mobilizers'. The median number of aphaeresis sessions was one. These results are very close in terms of effectiveness to those reported by Wood et al. 25 who used the same regimen of VP16 and G-CSF in 152 patients with MM. In that study, 99% of patients including those who received lenalidomide or radiotherapy collected at least 5 × 10 6 CD34+ cells/kg in 1-2 days and were considered as 'good mobilizers', median CD34+ cell number collected was 12 × 10 6 /kg, 85% of the patients reached the target dose of 8 × 10 6 /kg and 94% required only one aphaeresis session. All Group 2 patients were mobilized in the outpatients department and impact of the switch from CY to VP16 was important not only at an individual level but also at an institutional level. It has indeed permitted substantial decrease of the number of hospitalization days related to the mobilization from 133 days per year to 6 days per year and has permitted liberation of resources for other activities. The period of 127 hospitalization days liberated is equal to the period needed to perform eight ASCT for MM. The switch to VP16 has reduced the median number of aphaeresis needed from two with CY+G-CSF 5 to one, and hence has contributed to help the aphaeresis department to face the increasing demand of aphaeresis in both autologous and allogeneic settings. Grade 4 neutropenia, febrile neutropenia, hospitalization for IV antibiotics, RBC transfusions were significantly lower in patients mobilized with VP16+G-CSF 10 than in those mobilized with CY+G-CSF 5 . More than 90% of patients mobilized with VP16+G-CSF 10 did not require treatment for fever or transfusions. These differences in terms of efficacy and toxicity in favor of the VP16-G-CSF 10 regimen may be due either to the lower dose of G-CSF (5 μg/kg) used with CY or to the relatively high dose of CY (4 g/m 2 ) administered to group 1. In a retrospective study, 26 Hamadani et al. Abbreviations: CTD = cyclophosphamide-thalidomide-dexamethasone; CY = cyclophosphamide; ISS = International Staging System; VGPR = very good partial response.
PBSC mobilization regimens in newly diagnosed MM N Ben Abdejlil et al in the era of novel therapies (thalidomide, lenalidomide, bortezomib), G-CSF was used at 10 μg/kg in the two groups. Despite a more frequent previous lenalidomide use in the ID-CY group, the median number of the total CD34+ cells collected with this regimen was 16.6 × 10 6 /kg, which is close to the median number of 12.98 × 10 6 /kg collected in our patients mobilized with VP16+G-CSF 10 and almost twice the median number of 8.91 × 10 6 CD34+ cells/kg collected in our patients mobilized with CY+G-CSF 5 . Thus, the higher dose of G-CSF may explain partly the higher yield of PBSC harvested in our patients who received VP16 and in those who received ID-CY in the Hamadani study. However, in the study reported by Hamadani, the median number of aphaeresis sessions was two in the two groups like in patients mobilized with CY+G-CSF 5 in our study, whereas patients mobilized with VP16-G-CSF 10 underwent a median of only one aphaeresis session. These differences may be explained by the higher targeted dose of 10 × 10 6 CD34+/kg chosen in the Hamadani study. Lowering CY dose to 1.5-2 g/m 2 was reported to be less toxic, more practicable and convenient and depending on the study, less or as effective for PBSC mobilization as 4 g/m 2 . 27, 28 In the era of novel induction therapies, Hamadani et al. reported a lower total CD34+ cell yield obtained with LD-CY when compared with ID-CY (7.5 × 10 6 versus 16.6 × 10 6 CD34+ cells/kg) and a significantly higher proportion of patients unable to collect ⩾ 5 × 10 6 in the LD-CY group (30.9%) despite a significantly higher proportion of patients who received lenalidomide for induction in the ID-CY group. In the setting of low resources as it is the case in our country and in many other countries, it would be interesting to compare prospectively LD-CY (1.5 g/m 2 )+G-CSF 10 with VP16+G-CSF 10 administered in an outpatient setting. The two regimens would be compared for efficacy in mobilization of a sufficient number of PBSC to ensure realization of a second transplant, for toxicity and for hematopoietic recovery after ASCT.
ASCT was performed in 276 patients (93.5%); the median time to neutrophil engraftment and to platelet recovery was similar in the 2 groups.
In conclusion, this retrospective study showed that intermediate doses of VP16+G-CSF 10 could be administrated in the outpatients department, and allowed collection of significantly higher yield of PBSC in fewer aphaeresis sessions than CY+G-CSF 5 . It was associated with a significant reduction of the number of hospitalization days, allowed liberation of resources in the clinical and aphaeresis departments, was less toxic than CY+G-CSF 5 and resulted in successful engraftment. Abbreviations: ASCT = autologous peripheral blood stem cell transplantation; CY = cyclophosphamide.
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